Market Overview

UPDATE: Cantor Fitzgerald Maintains Life Technologies at Hold Following Test Results

Related LIFE
IPO Outlook: Down-Home Cookin', Fast-Casual Bojangles' Sizzles Investors
Market Wrap For January 16: Markets End Two Day Winning Streak
Week Ahead: 14 IPOs Planned For The Week Of May 4 (Seeking Alpha)

Cantor Fitzgerald reiterated its Hold rating and $47 price target on Life Technologies (NASDAQ: LIFE).

Cantor Fitzgerald noted, "Earlier today, LIFE announced the launch of a CLIA-based, lung cancer risk stratification test for early stage lung cancer. The test (Pervenio Lung RS) was obtained through the acquisition of Pinpoint Genomics (July 25) and immediately leverages CLIA capabilities from the Navigenics acquisition (July 16). Based on currently available data, we are uncertain about the longer-term clinical utility of the test (other than to treat most early stage patients more aggressively), although we are turning positive on the tangible progress LIFE continues to make in building diagnostics capabilities."

Life Technologies closed at $48.92 on Tuesday.

Latest Ratings for LIFE

Aug 2013BairdDowngradesOutperformNeutral
May 2013Credit AgricoleDowngradesOutperformUnderperform
May 2013JefferiesDowngradesBuyHold

View More Analyst Ratings for LIFE
View the Latest Analyst Ratings

Posted-In: Cantor FitzgeraldAnalyst Color Reiteration Intraday Update Analyst Ratings


Related Articles (LIFE)

Around the Web, We're Loving...